Currently, numerous small molecule inhibitors targeting PRMT5 have been developed, exhibiting anti-tumor effects in a variety of solid and hematological tumors, with some advancing to Phase I or Phase II clinical trials (Table 2). Here, PRMT5 is linked to neoplasm.